Featured Publications
Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers
Aguolu OG, Willebrand K, Elharake JA, Qureshi HM, Kiti MC, Liu CY, Mesa A, Nelson K, Jenness S, Melegaro A, Ahmed F, Yildirim I, Malik FA, Lopman B, Omer SB. Factors influencing the decision to receive seasonal influenza vaccination among US corporate non-healthcare workers. Human Vaccines & Immunotherapeutics 2022, 18: 2122379. PMID: 36136345, PMCID: PMC9746537, DOI: 10.1080/21645515.2022.2122379.Peer-Reviewed Original ResearchMeSH KeywordsAdultCOVID-19FemaleHumansInfluenza VaccinesInfluenza, HumanMaleUnited StatesVaccinationWorkplaceYoung AdultConceptsInfluenza vaccinationNon-healthcare workersInfluenza vaccinePromotion messagesWorkplace vaccination programsSeasonal influenza vaccinationInfluenza vaccine acceptancePublic health authoritiesLogistic regression modelsInfluenza seasonPhysician recommendationVaccination acceptanceVaccine accessibilityVaccine acceptanceSevere outcomesVaccination programPromotion interventionsUS adultsWork absenceVaccinationVaccination decisionsHealth authoritiesSignificant mortalityUnderstanding predictorsSignificant predictors
2020
Microbiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease
Kao CM, Yee ME, Maillis A, Lai K, Bakshi N, Rostad BS, Jerris RC, Lane PA, Yildirim I. Microbiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease. Pediatric Blood & Cancer 2020, 67: e28517. PMID: 32710705, PMCID: PMC8369475, DOI: 10.1002/pbc.28517.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMethicillin-susceptible Staphylococcus aureusMagnetic resonance imagingAntibiotic treatmentOperative culturesCell diseaseLarge tertiary pediatric centerPrescribed antibiotic treatmentTertiary pediatric centerCulture-positive casesKey presenting symptomsChildren ages 6Bone painMicrobiologic etiologyPresenting symptomPediatric centersBone infarctsMedical chartsMicrobiologic findingsRadiographic featuresImaging featuresOsteomyelitisProbable osteomyelitisDiagnostic codingTissue debridementInitial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosingBrincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series
Londeree J, Winterberg PD, Garro R, George RP, Shin S, Liverman R, Serluco A, Romero R, Yildirim I. Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series. Pediatric Transplantation 2020, 24: e13769. PMID: 32558134, DOI: 10.1111/petr.13769.Peer-Reviewed Original ResearchConceptsPediatric SOT recipientsSOT recipientsCase seriesSevere diseasePediatric solid organ transplant recipientsSolid organ transplant recipientsType of allograftMainstay of treatmentOrgan transplant recipientsSeverity of diseaseHuman adenovirus infectionHAdV diseaseHAdV viremiaPediatric recipientsTransplant recipientsHAdV infectionDisease courseAntiviral therapySignificant morbidityDisease presentationUS FDAAdenovirus infectionBrincidofovirDiseaseRecipients
2019
Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp
McAteer J, Jernigan S, Mao C, Gonzalez MD, Watson RJ, Liverman R, Angelo M, M. H, Shane A, Yildirim I. Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp. Pediatric Transplantation 2019, 24: e13649. PMID: 31885132, DOI: 10.1111/petr.13649.Peer-Reviewed Original ResearchConceptsTransplant recipientsSolid organ transplant recipientsKidney transplant recipientsRetrospective cohort studyOrgan transplant recipientsPediatric transplant recipientsOverall attack rateAcute rejection eventsLong-term interventionsImmunosuppressive therapySymptom durationCohort studyRisk factorsNotable burdenStool specimensCryptosporidiosis infectionEtiologic agentRejection eventsAttack rateFurther outbreaksInfectionRecipientsCryptosporidium hominisCryptosporidiosisOutbreak
2018
Impact of Pharmacy-Initiated Interventions on Influenza Vaccination Rates in Pediatric Solid Organ Transplant Recipients
Gattis S, Yildirim I, Shane AL, Serluco S, McCracken C, Liverman R. Impact of Pharmacy-Initiated Interventions on Influenza Vaccination Rates in Pediatric Solid Organ Transplant Recipients. Journal Of The Pediatric Infectious Diseases Society 2018, 8: 525-530. PMID: 30307524, DOI: 10.1093/jpids/piy095.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsPediatric SOT recipientsInfluenza vaccination ratesOrgan transplant recipientsSOT recipientsTransplant recipientsInfluenza infectionVaccination ratesVaccination coveragePediatric solid organ transplant recipientsSubsequent graft dysfunctionHeart transplant recipientsInfluenza vaccination coveragePre-post study designNumber of patientsRate of vaccinationGraft dysfunctionInfluenza immunizationInfluenza vaccinationChart reviewPharmacy interventionsMedian timeVaccine coverageTransplant servicesInfluenza rates
2015
Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine
Yildirim I, Shea KM, Pelton SI. Pneumococcal Disease in the Era of Pneumococcal Conjugate Vaccine. Infectious Disease Clinics Of North America 2015, 29: 679-697. PMID: 26610421, PMCID: PMC4662776, DOI: 10.1016/j.idc.2015.07.009.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccinePneumococcal diseaseConjugate vaccineOtitis mediaUniversal immunizationAcute otitis mediaInvasive pneumococcal diseaseCase fatality rateVulnerable pediatric patientsSpectrum of serotypesCause pneumoniaPediatric patientsComorbid conditionsHealthy childrenFatality rateDiseaseHost susceptibilityImmunizationVaccineHigh rateChildrenEmpyemaMastoiditisPneumoniaPatients